MedTrace Logo

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

NCT03578354 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-07-01

No results posted yet for this study

Summary

This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.

Conditions

  • Vestibular Migraine
  • Migraine Disorders
  • Vestibular Diseases

Interventions

DRUG

4-aminopyridine

an oral drug to be swallowed

DRUG

Atenolol

an oral drug to be swallowed

OTHER

Placebo

a masked placebo to be swallowed

Sponsors & Collaborators

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2023-01-31
Completion
2024-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03578354 on ClinicalTrials.gov